We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Medarex and PharmAthene have announced the allowance of an investigational new drug application filed with the FDA to initiate a Phase I clinical trial for Valortim, a monoclonal antibody targeting the bacillus anthracis protective antigen.
Provectus Pharmaceuticals has announced that the first patients have completed treatment in its Phase I clinical trial of PV-10, also known as Provecta.
Nuvelo has announced the publication of clinical data from the Phase I trial of its lead product candidate, alfimeprase, in the August issue of the Journal of Vascular and Interventional Radiology.
Germany-based Schwarz Pharma has announced the first headline data from its Phase III program with the active compound lacosamide for diabetic neuropathic pain.
Threshold Pharmaceuticals has initiated a Phase III clinical trial as part of a registrational program of its investigational drug candidate TH-070 (lonidamine).
Novartis Pharmaceuticals announced that the FDA has approved Diovan (valsartan), the most prescribed ARB (angiotensin receptor blocker) in the U.S. and worldwide, for a new indication to reduce cardiovascular death in patients at high risk (with left ventricular failure or left ventricular dysfunction) following a heart attack.
PowderMed, an immunotherapeutics, has announced that it has progressed its H5N1 avian influenza vaccine program into the final stages of preclinical development.
Preliminary experimental data from cellular tests conducted by university scientists working under a research grant sponsored by Marc Pharmaceuticals has demonstrated that a betulinol derivative inhibits HIV-1 replication by more than 90 percent with no evidence of detrimental changes to cell viability.
Genelabs Technologies today announced that a non-nucleoside compound from its internal hepatitis C virus (HCV) drug discovery program has advanced into preclinical development.